Dr Carl Firth, the company’s chief executive, said: “Taiwan has a strong biotech public market, and investors are knowledgeable, experienced and have strong interest in this industry.” Aslan raised US$23 million (S$32.3 million) in a pre-IPO funding round …
( read original story …)